If translated to the human situation [...], we could dream of a scenario in which any implant pretreated with AlchiMedics’ CD31 technology will not need a systemic administration of antiplatelet agent such as P2Y12. When I was exposed in depth to the complex cellular biology mechanisms of this CD31 coating, I had the same reaction as 25 years ago when I saw for the first time the preclinical work on a stent eluting rapamune, [...] and by now there are millions of patients that have benefited from that technology and… I have the same intuitive feeling that something similar could happen with the introduction of CD31 on any human implants. Who will grab that opportunity? Time will tell us.
Pr Patrick W. Serruys: Established Professor of Interventional Medicine & Innovation, University of Galway